Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus PYLARIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus PYLARIFY.
CIS-MDP vs PYLARIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
1 mg/kg IV bolus administered once.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical